Jeremy M . Shefner, MD, PhD
Professor
Department
Neurology (Phoenix)
Position
Professor
General
- Brooks Benjamin Rix, Jorgenson James A, Newhouse Barbara J, Shefner Jeremy M, Agnese Wendy, Edaravone in the treatment of amyotrophic lateral sclerosis: efficacy and access to therapy - a roundtable discussion 2018
Articles
- Handbook of Clinical Neurology
Andrews Jinsy A., Shefner Jeremy M., Clinical neurophysiology of anterior horn cell disorders [Book Chapter] 2019
Publications
- Amyotrophic lateral sclerosis and frontotemporal degeneration
Rudnicki Stacy A., Wei Jenny, Gebrehiwet Paulos, Kupfer Stuart, Malik Fady I., Meng Lisa, Simkins Tyrell, Wolff Andrew A., Shefner Jeremy M., Participant, site personnel and sponsor perspectives on decentralized trial features in COURAGE-ALS: a randomized clinical trial
26:7-8, p. 812 - 820 2025 - Journal of neuromuscular diseases
Simkins (lead) Tyrell, Kupfer Stuart, Shefner Jeremy M, Malik Fady I, van Eijk Ruben PA, Meng Lisa, Rudnicki Stacy A, Wei Jenny, Application of the ENCALS predictive survival model in assessing the effect of the 24/44 inclusion criteria in FORTITUDE-ALS
12:5, p. 679 - 682 2025 - Lancet neurology
Ladha Shafeeq, Wang Jianing, Chibnik Lori B., Quintana Melanie, Macklin Eric A., Saville Benjamin R., Detry Michelle A., Vestrucci Matteo, Paulon Giorgio, McGlothlin Anna, Shefner Jeremy, , Safety and efficacy of trehalose in amyotrophic lateral sclerosis (HEALEY ALS Platform Trial): an adaptive, phase 2/3, double-blind, randomised, placebo-controlled trial
24:6, p. 500 - 511 2025 - JAMA neurology
Shefner Jeremy M., Andrews Jinsy A., Cudkowicz Merit E., Genge Angela, Hardiman Orla, Al-Chalabi Ammar, Chio Adriano, Corcia Philippe, Couratier Philippe, De Carvalho Mamede, , Reldesemtiv in Amyotrophic Lateral Sclerosis: Results From the COURAGE-ALS Randomized Clinical Trial
82:5, p. 477 - 485 2025 - Amyotrophic lateral sclerosis and frontotemporal degeneration
Simkins Tyrell J., Rudnicki Stacy A., Kupfer Stuart, Malik Fady I., Meng Lisa, Bowser Robert, Wei Jenny, Shefner Jeremy M., Plasma neurofilament analysis in VITALITY-ALS
26:1-2, p. 103 - 112 2025 - Amyotrophic lateral sclerosis and frontotemporal degeneration
Rudnicki Stacy A., Corcia Philippe, Al-Chalabi Ammar, Andrews Jinsy A., Chio Adriano, Genge Angela, Couratier Philippe, Cudkowicz Merit E., De Carvalho Mamede, Hardiman Orla, Shefner Jeremy M., , Hospitalizations as an outcome measure in COURAGE-ALS
26:7-8, p. 802 - 811 2025 - Amyotrophic lateral sclerosis and frontotemporal degeneration
Shefner Jeremy M, Kupfer Stuart, Jacobsen Bill, Wolff Andrew A, Malik Fady I, Meng Lisa, Wei Jenny, Rudnicki Stacy A, Relationship between quantitative strength and functional outcomes in the phase 2 FORTITUDE-ALS trial
25:1-2, p. 162 - 169 2024 - Brain (London, England : 1878)
Shefner Jeremy, Musaro Antonio, Robitaille Richard, de Carvalho Mamede, Rutkove Seward, Ludolph Albert, Dupuis Luc, Ngo Shyuan, Lunetta Christian, Steyn Frederik, Skeletal muscle in amyotrophic lateral sclerosis
146:11, p. 4425 - 4436 2023 - Amyotrophic lateral sclerosis and frontotemporal degeneration
Shefner Jeremy M., Couratier Philippe, Cudkowicz Merit E., Genge Angela, De Carvalho Mamede, Al-Chalabi Ammar, Cockroft Bettina M., Corcia Philippe, Andrews Jinsy A., Chio Adriano, , COURAGE-ALS: a randomized, double-blind phase 3 study designed to improve participant experience and increase the probability of success
24:5-6, p. 523 - 534 2023 - Journal of medical economics
Gebrehiwet Paulos, Miller Timothy M., Shefner Jeremy M., Sarocco Phil, Meng Lisa, Rudnicki Stacy A., Wei Jenny, Wolff Andrew A., Butzner Michael, Hughes Dyfrig A., Chiò Adriano, Andrews Jinsy A., Genge Angela, Jackson Carlayne E., Lechtzin Noah, Health utilities and quality-adjusted life years for patients with amyotrophic lateral sclerosis receiving reldesemtiv or placebo in FORTITUDE-ALS
26:1, p. 488 - 493 2023 - Muscle & nerve
Miller Robert G., Mitsumoto Hiroshi, Zhang Rongzhen, Bracci Paige M., Azhir Ari, Barohn Richard, Bedlack Richard, Benatar Michael, Berry James D., Cudkowicz Merit, Kasarskis Edward J., Manousakis Georgios, Walk David, Oskarsson Bjorn, McGrath Michael S., Shefner Jeremy, Phase 2B randomized controlled trial of NP001 in amyotrophic lateral sclerosis: Pre-specified and post hoc analyses
66:1, p. 39 - 49 2022 - Amyotrophic lateral sclerosis and frontotemporal degeneration
Stegmann Gabriela M., Liss Julie, Hahn Shira, Duncan Cayla J., Rutkove Seward B., Shefner Jeremy M., Berisha Visar, Estimation of forced vital capacity using speech acoustics in patients with ALS
22:S1, p. 14 - 21 2021 - Nature reviews. Neurology
Kiernan Matthew C., Talbot Kevin, Vucic Steve, Al-Chalabi Ammar, McDermott Christopher J., Hardiman Orla, Shefner Jeremy M., Van den Berg Leonard H., Huynh William, Cudkowicz Merit, Talman Paul, Dharmadasa Thanuja, Wicks Paul, Reilly Claire, Turner Martin R., Improving clinical trial outcomes in amyotrophic lateral sclerosis
17:2, p. 104 - 118 2021 - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Shefner Jeremy M., Malik Fady I., Andrews Jinsy A., Meng Lisa, Rudnicki Stacy A., Wolff Andrew A., Cockroft Bettina M., Cudkowicz Merit E., Hardiman Orla, Lee Jacqueline H., A phase III trial of tirasemtiv as a potential treatment for amyotrophic lateral sclerosis
20:7-8, p. 584 - 594 2019 - Neurology
Andrews Jinsy A., Bruijn Lucie I., Shefner Jeremy M., ALS drug development guidances and trial guidelines: Consensus and opportunities for alignment
93:2, p. 66 - 71 2019 - Neurology
Darras Basil T., Montes Jacqueline, Chiriboga Claudia A., Iannaccone Susan T., Swoboda Kathryn J., Mignon Laurence, Xia Shuting, Bennett C. Frank, Bishop Kathie M., Shefner Jeremy M., Gheuens Sarah, De Vivo Darryl C., Green Allison M., Sun Peng, Bhan Ishir, Schneider Eugene, Farwell Wildon, Nusinersen in later-onset spinal muscular atrophy: Long-term results from the phase 1/2 studies
92:21, p. e2492 - e2506 2019 - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Rutkove Seward B., Qi Kristin, Liss Julie, Berisha Visar, Shefner Jeremy M., Shelton Kerisa, ALS longitudinal studies with frequent data collection at home: study design and baseline data
20:1-2, p. 61 - 67 2019 - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Shefner Jeremy M., Rutkove Seward B., Caress James B., Benatar Michael, David William S., Cartwright Michael S., Macklin Eric A., Bohorquez Jose L., Reducing sample size requirements for future ALS clinical trials with a dedicated electrical impedance myography system
19:7-8, p. 555 - 561 2018 - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Lechtzin Noah, Shefner Jeremy, Van den Berg Leonard H., Andrews Jinsy A., Genge Angela, Cudkowicz Merit E., Mitsumoto Hiroshi, Mora Jesus S., Hardiman Orla, de Carvalho Mamede, Respiratory measures in amyotrophic lateral sclerosis
19:5-6, p. 321 - 330 2018 - European Journal of Neurology
Smith R. A., Macklin E. A., Myers K. J., Pattee G. L., Goslin K. L., Meekins G. D., Green J. R., Shefner J. M., Pioro E. P., Assessment of bulbar function in amyotrophic lateral sclerosis: validation of a self-report scale (Center for Neurologic Study Bulbar Function Scale)
25:7, p. 907 - e66 2018 - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Andrews Jinsy A., Lee Jacqueline, Cudkowicz Merit E., Hardiman Orla, Meng Lisa, Bian Amy, Wolff Andrew A., Malik Fady I., Shefner Jeremy M., VITALITY-ALS, a phase III trial of tirasemtiv, a selective fast skeletal muscle troponin activator, as a potential treatment for patients with amyotrophic lateral sclerosis: study design and baseline characteristics
19:3-4, p. 259 - 266 2018 - Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration
Meng Lisa, Wolff Andrew, Shefner Jeremy M., Andrews Jinsy, Jordan Scott, Bian Amy, Profile of medical care costs in patients with amyotrophic lateral sclerosis in the Medicare programme and under commercial insurance
19:1-2, p. 134 - 142 2018 - JAMA Neurology
Andrews Jinsy A., Bozik Michael E., Kulke Sarah F., Rudnicki Stacy A., Wolff Andrew A., Malik Fady I., Shefner Jeremy M., Meng Lisa, Association Between Decline in Slow Vital Capacity and Respiratory Insufficiency, Use of Assisted Ventilation, Tracheostomy, or Death in Patients With Amyotrophic Lateral Sclerosis
75:1, p. 58 - 58 2018
Presentations
- Invited Speaker, 2019 California ALS Summit, Irvine CA. 2019
- Invited Speaker, 2018 Northeast ALS Clinical Trials Consortium Annual Meeting, Clearwater FL. 2018
- Plenary Speaker, 2018 FightMND Australasion ALS Symposium, Melbourne, Australia. 2018
- Lisa Krivickas Lecturer, Massachusetts General Hospital, Boston, MA. 2018
- Invited Speaker, Packard Symposium on ALS, Baltimore, MD. 2017
- Grand Rounds, Houston Methodist Medical Center. 2017
- Grand Rounds, University of Arizona College of Medicine. 2017